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Introduction: To characterize cardiac complications in acute ischemic stroke (AIS) patients admitted
from an urban emergency department (ED).
Methods: Retrospective cross-sectional study evaluating AIS patients admitted from the ED within 24
hours of symptom onset who also had an echocardiogram performed within 72 hours of admission.
Results: Two hundred AIS patients were identified with an overall in-hospital mortality rate of 8% (n¼
16). In our cohort, 57 (28.5%) of 200 had an ejection fraction less than 50%, 35 (20.4%) of 171 had
ischemic changes on electrocardiogram (ECG), 18 (10.5%) of 171 presented in active atrial fibrillation,
21 (13.0%) of 161 had serum troponin elevation, and 2 (1.1%) of 184 survivors had potentially lethal
arrhythmias on telemetry monitoring. Subgroup analysis revealed higher in-hospital mortality rates
among those with systolic dysfunction (15.8% versus 4.9%; P ¼ 0.0180), troponin elevation (38.1%
versus 3.4%; P , 0.0001), atrial fibrillation on ECG (33.3% versus 3.8%; P ¼ 0.0003), and ischemic
changes on ECG (17.1% versus 6.1%; P¼ 0.0398) compared with those without.
Conclusion: A proportion of AIS patients may have cardiac complications. Systolic dysfunction,
troponin elevation, atrial fibrillation, or ischemic changes on ECG may be associated with higher in-
hospital mortality rates. These findings support the adjunctive role of cardiac-monitoring strategies in
the acute presentation of AIS. [West J Emerg Med. 2011;12(4):414–420.]
INTRODUCTION
Acute central nervous system injury has long been
associated with myocardial injury and dysfunction.
1–3 Some
have implicated serum catecholamine elevations in particular
with strokes involving the insular cortex,
4–6 but the
mechanisms underlying this relation are poorly understood in
acute ischemic stroke (AIS). Cardiac dysfunction in stroke
patients may be particularly damaging. Within the territory of
tissue affected by an AIS (ie, the ischemic penumbra) intrinsic
autoregulation of the vasculature is lost, rendering cerebral
blood ﬂow directly dependent on cardiac function.
7–9
However, a paucity of investigators have evaluated the
incidence, role, and impact of cardiac function and
complications with AIS. Emergency physicians responsible for
managing AIS currently have no practice guidelines promoting
cardiovascular monitoring beyond blood pressure control,
continuous telemetry monitoring, cardiac biomarkers, and
admission electrocardiograms (ECG).
10 Once admitted, AIS
patients undergo inpatient echocardiograms evaluating for a
cardioembolic source, with no recommendations regarding
management of systolic or diastolic dysfunction. The
identiﬁcation of cardiac comorbidity is important, as future
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subset of stroke patients.
11
We designed this preliminary study to reinforce the limited
existing literature characterizing the prevalence of cardiac
complications in the setting of AIS. For our primary outcome,
we hypothesized that a signiﬁcant proportion of AIS patients
have systolic dysfunction on echocardiography. As alternative
outcomes, we hypothesized that a signiﬁcant proportion of AIS
patients also have further myocardial or hemodynamic
abnormalities manifested by ECG abnormalities, diastolic
dysfunction on echocardiography, serum troponin elevation,
elevated systolic blood pressure, or the presence of
hemoconcentration, suggesting a low-volume state.
METHODS
This study was a single-reviewer retrospective cross-
sectional analysis using deﬁned markers to characterize the
cardiac complications and the hemodynamic proﬁle of AIS
patients. Our primary outcome was the frequency of systolic
dysfunction, deﬁned as an ejection fraction (EF) on
echocardiography less than 50%, as previously deﬁned in the
cardiology literature.
12 Echocardiograms were read by staff
cardiologists at our hospital as a part of the standard care for all
AIS patients.
Secondary outcomes were the presence of ECG
abnormalities, diastolic dysfunction on echocardiography,
serum troponin I elevation (greater than 0.04 mg/dL), an
elevated initial systolic blood pressure, and the presence of a
hemoconcentrated red blood cell volume. ECG abnormalities
were originally read by a staff cardiologist at our hospital as a
part of the formal medical record. The interpretations were then
collectedbyastudyinvestigator.AnabnormalECGincludedthe
presence of ischemic changes on ECG (ie, T-wave inversions,
ST-segment changes) or the presence of arrhythmias (ie, atrial
ﬁbrillation). Diastolic dysfunction on echocardiography was
measured in one of three ways: ‘‘E’’ (early atrial ﬁlling) to ‘‘A’’
(atrialkick)waveformreversal,tissueDopplermeasurementson
transthoracic echocardiography, or pulmonary vein ﬂow on
transesophageal echocardiography. Serum troponinvalueswere
included if the blood was drawn in the emergency department
(ED)orwithin24hoursofadmission.Anelevatedinitialsystolic
blood pressure was represented by the initial blood pressure
measurement in the ED. The presence of hemoconcentration
was measured by comparing the initial ED hemoglobinvalue to
the mean of up to three prior outpatient serum hemoglobin
measurements. Although this is a largely untested and indirect
method for assessing ﬂuid volume status, we assumed a low-
ﬂuid-volumestatewaspresentiftheEDhemoglobinvalueswere
greater than the mean of three outpatient hemoglobin values.
The study was performed at an academic tertiary care
hospital seeing more than 110,000 ED visits per year. The
protocol and procedures were approved by the Institutional
Review Board for human research. This study was a chart
review of adult patients admitted from the ED over a 1-year
period with the diagnosis of AIS. It was determined a priori that
200 patients would be included. Patients were identiﬁed from
the ED electronic medical record, which tracked all admissions
from the ED. Patients were identiﬁed from the electronic
medical record for being admitted with a diagnosis of stroke,
ischemic stroke, or cerebral vascular accident between January
1, 2004, and December 31, 2004. After a patient list was
generated from the medical record, a senior resident
investigator (C.W.) under the supervision and monitoring of
senior faculty investigators (C.L. and E.R.) used a standardized
data collection and glossary of terms to extract demographic
and clinical data. The faculty mentors were involved in study
design, Institutional Review Board approval, creation of the
data-collection form, creation of a database, and were involved
in the analysis of the data. Faculty mentors met with the
resident on a regular basis to ensure compliance, to review
questions and unforeseen issues related to data collection or
abstraction, and were involved in the analysis of data.
Inclusion criteria were patients diagnosed with AIS in the
ED who presented within 24 hours of onset of symptoms, and
patients who had a cardiac echocardiogram performed within
72 hours of hospital admission. Exclusion criteria were age
younger than 18 years, evidence of cerebral hemorrhage on
initial head computed tomography, resolution of neurologic
symptoms in the ED or ED diagnosis of transient ischemic
attack (TIA), or the presence of documented chest pain in the
ED.
For our primary analysis, sample size calculation, given
that past literature
13,14 demonstrated that 13% to 29% of AIS
patients have cardiac dysfunction, we estimated sufﬁcient
power with a sample size of at least 200 AIS patient subjects to
detect the prevalence of impaired contractility (EF less than
50%) withinþ5% of the true prevalence. Results were reported
with the mean, standard deviation, and 95% conﬁdence interval
where indicated. Paired and unpaired t tests were used to
compare means between different groups. The Fisher Exact
Test was used in subgroup analysis for comparing in-hospital
mortality rates among patients with systolic dysfunction, ECG
abnormalities, or serum troponin I elevation. Statistical
signiﬁcance was indicated by an alpha error less than 0.05.
For our primary analysis, the established inclusion and
exclusion criteria assured that no data were missing and that all
patients had a measurement of contractility on
echocardiography. For our secondary analyses, we aimed to
estimate the prevalence of each abnormality (ie, troponin
elevation), and to compare the difference in mortality rate
contrasted to patients without the abnormalities (ie, patients
with abnormal versus normal troponin levels). To estimate
prevalence, we used the number of patients who actually had
these tests performed as the denominator for calculating the
prevalence of abnormal values (ie, the percentage of patients
with abnormal ECGs). To compare differences in mortality
rates, we ﬁrst established as a prerequisite that at least 80% of
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comparison. We then used the total patient sample (n¼200) as
the denominator for comparing mortality rates by using the
Fisher Exact Test between the different subgroups.
If other variables (ie, systolic blood pressure, National
Institutes of Health stroke scale [NIHSS]) were not available in
the ED medical record, then they would be acquired from the
inpatient medical records, with the ﬁrst value being reported
being the one that was used. If the NIHSS was not available in
the inpatient records, then it would be calculated
retrospectively
15 by the data extractor under the supervision of
senior faculty. If a comprehensive admission neurologic
examination was not documented in the medical record, then
that patient was not included in analyses using the NIHSS. For
the assessment of hemoconcentration, missing inpatient or
outpatient hemoglobin values excluded patients from this
alternative analysis.
RESULTS
In total, 398 patients with an ED admission diagnosis of
stroke, ischemic stroke, or cerebral vascular accident were
identiﬁed; 58 were excluded for having cerebral hemorrhage on
initial imaging; and 140 were excluded for not meeting
inclusion criteria, including being admitted with a primary
diagnosis other than AIS or presenting with a duration of
symptoms longer than 24 hours. Because our acute stroke
protocol includes an echocardiogram on admission for all AIS
patients, only 8 patients were excluded because
echocardiograms were not performed within 72 hours of
hospital admission. Cumulatively, 200 patients met inclusion
criteria.
Demographics of our patient population are summarized in
Table 1. Of our patients, 57.5% were women. The mean age
was 65.2þ 14.9 years old. The most common comorbidities
were hypertension (62%), diabetes (24.5%), and
hyperlipidemia (21.5%). Of the patients, 18.5% previously had
an AIS or TIA; 8.5% of patients had a history of congestive
heart failure. For all patients, the mean initial systolic blood
pressure for patients in the ED was 168.9 mm Hgþ37.8 (95%
conﬁdence interval [CI], 161.3 mm Hg to 176.5 mm Hg).
Among all patients, the overall in-hospital mortality rate was
8% (n¼16). The mean initial NIHSS for identiﬁed patients was
7.88þ 6.15 (95% CI, 7.00 to 8.77; n¼ 188).
Of the total sample of patients, 57 (28.5%) had evidence of
systolic dysfunction deﬁned as an EF less than 50% on
echocardiograms performed within 72 hours of hospital
admission; 38 (18%) patients had evidence of diastolic
dysfunction on echocardiograms, as indicated by E to A
reversal, abnormal tissue Doppler, or abnormal pulmonary vein
ﬂow. Of the patients, 171 (85.5%) had ECGs performed in the
ED; 35 (20.4%) patients had ischemic changes on ECG deﬁned
as T-wave inversions or ST-segment depressions. No patients
had ST-segment elevations in concurrent ECG leads. Eighteen
(10.5%) patients presented in active atrial ﬁbrillation.
Among laboratory tests, 161 (80.5%) patients had serum
troponin I levels checked in the ED or within 24 hours of
hospitalization, with 21 (13.0%) having elevated values; 116
(58.0%) had outpatient hemoglobin values available for
assessment of hemoconcentration, the surrogate marker for a
low-volume state. Mean hemoglobin levels on initial
presentation in the ED were higher contrasted to outpatient
baseline values (13.5þ1.7 g/L versus 12.6þ1.5 g/L; n¼116,
P ¼ 0.0001 by using a paired t test).
Twenty-ﬁve patients received thrombolysis, with 19
having improvement of symptoms before hospital discharge.
Among patients receiving TPA and having documented NIHSS
Table 1. Demographics of patient population.
Demographic data No. %
Female 115 57.5
Hypertension 124 62
Diabetes mellitus 49 24.5
Congestive heart failure 17 8.5
Hyperlipidemia 43 21.5
Acute ischemic stroke or transient ischemic
attack 37 18.5
Carotid endarterectomy 1 0.5
Intracranial bleed 1 0.5
Coronary artery disease or acute myocardial
infarction 24 12
Atrial fibrillation 15 7.5
Cancer 10 5
Drug use or alcoholism 12 6
Tobacco use 10 5
Connective tissue/autoimmune disease 9 4.5
Pulmonary disease (chronic obstructive
pulmonary disease, asthma, pulmonary
fibrosis, other) 15 7.5
Psychiatric illness (depression, bipolar,
schizophrenia, other) 5 2.5
Thyroid disorder 6 3
Peripheral vascular disease 7 3.5
Gastrointestinal bleed 2 1
Abdominal aortic aneurysm repair 1 0.5
Pacemaker 5 2.5
Other arrhythmias 1 0.5
Seizure disorder 7 3.5
End-stage renal disease 3 1.5
Chronic kidney disease 3 1.5
Dementia 3 1.5
Pulmonary embolism 1 0.5
Migraine headaches 1 0.5
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was 12.8þ9.82, and the mean predischarge NIHSS was 6.4þ
9.3 (P¼ 0.0775; n¼ 15). Two patients had symptomatic
hemorrhagic transformation, deﬁned as an escalation of NIHSS
with evidence of cerebral hemorrhage on serial neuroimaging.
One patient had asymptomatic hemorrhagic transformation.
Patients with an NIHSS greater than 10, contrasted with
those with an NIHSS of 10 or less, had higher rates of in-
hospital mortality, serum troponin elevation, and ischemic
changes on ECG. A trend existed toward a higher rate of
systolic dysfunction among patients with more-severe strokes
(Table 2). We did not observe mortality differences when
evaluating blood pressure or for the presence of
hemoconcentration. Subgroup analysis (Figure) with the Fisher
Exact Test revealed higher in-hospital mortality rates among
patients with systolic dysfunction (15.8% versus 4.9%; P ¼
0.0180),troponin I elevation (38.1% versus 3.4%, P , 0.0001),
atrial ﬁbrillation on initial ECG (33.3% versus 3.8%; P ¼
0.0003), and ischemic changes on initial ECG (17.1% versus
6.1%; P¼0.0398). Two survivors (1.1%;n¼184) had multiple
(more than 3) episodes of nonsustained ventricular tachycardia
documented on telemetry during hospitalization.
DISCUSSION
Heart–brain interactions are more comprehensively
described by neurosurgical investigators in the setting of a
speciﬁc type of hemorrhagic stroke, the acute subarachnoid
hemorrhage (SAH). Indeed, in neurosurgical models and
clinical studies, 40% to 100% with SAH can have ECG
changes or arrhythmias,
16–20 11% to 21% can have myocardial
enzyme elevation,
17,19,20 and 2% to 30% may have left
ventricular dysfunction manifested by hypokinetic wall-motion
abnormalities on echocardiography.
17–20 Compared with AIS,
heart–brain interactions in SAH have been more widely
investigated,
21–34 with literature describing reversible
myocardial stunning,
35 histologic evidence of myocardial
necrosis,
36 elevation of natriuretic factors,
37,38 secondary
neurogenic pulmonary edema,
39 elevation of systemic plasma
catecholamines,
40,41 and impairment of regional myocardial
perfusion.
42,43 Additionally, in the neurosurgical literature,
hemodynamic manipulations have been more rigorously
evaluated, speciﬁcally for the management of cerebral
vasospasm after SAH.
44
In the setting of AIS, cardiac complications may be
particularly damaging with the high incidence of underlying
coronary artery disease,
3,45 and given evidence that within the
ischemic penumbra intrinsic autoregulation of the vasculature
is often lost rendering cerebral blood ﬂow directly dependent
upon cardiac function.
7,8 Our data compliments the limited
existing literature performed by other investigators suggesting
that 13% to 29%
13,14 of AIS patients may have systolic
dysfunction on echocardiography, 35% to 74%
1–3,46 may have
ischemic changes on ECG, and 1% to17%
1,3,4,46–48 may have
elevated serum troponin levels, which has been shown to be
associated with higher mortality rates.
47,48
In our study, we used the indirect surrogate markers of
initial systolic blood pressure and hemoconcentration to
represent an estimate of afterload and preload, respectively.
Although use of these surrogate markers is untested and
affected by potential biases, our ﬁndings were compatible with
existing literature. Current literature demonstrates that AIS
patients may present with elevated afterload represented by an
elevated mean arterial pressure.
49 Only 1 study to our
knowledge has evaluated preload, reporting a mean central
venous pressure of 4.5 mm Hg.
50 Additionally, even though this
variable was not evaluated in our study, 2 studies to our
knowledge have recorded cardiac output in a small sample of
AIS patients.
50,51
Regarding structural systolic function on
Table 2. Rates of troponin elevation, ischemic electrocardiogram
changes, systolic dysfunction on echocardiogram, and in-hospital
mortality for patients stratified into stroke-severity groups (NIHSS ,
10 and NIHSS . 10).
NIHSS , 10
(n ¼ 132)
NIHSS . 10
(n ¼ 56) P value
Troponin elevation 6.8% (9) 21.4% (12) 0.009
Ischemic changes on
electrocardiogram 12.1% (16) 26.8% (15) 0.018
Systolic dysfunction 24.2% (32) 39.3% (22) 0.052
Died in hospital 4.5% (6) 17.9% (10) 0.007
NIHSS, National Institutes of Health stroke scale.
Figure. In-hospital mortality rates among patients with troponin
elevation, atrial fibrillation, systolic dysfunction, and ischemic
electrocardiogram (ECG) changes (n ¼200). (P , 0.05 for all
groups using the Fisher Exact Test.)
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of patients, which is similar to that in other cited
investigations.
13,14 Although our design did not have a control
group or allow follow-up echocardiography to determine
whether this ﬁnding was only transient, only 8.5% of our
patients had a pre-existing diagnosis of congestive heart failure.
Thus it is possible that a large proportion of our patients may
have had an acute change in cardiac contractility temporally
related to their AIS (ie, either before or after). Nevertheless,
similar to other investigators’ observations that undifferentiated
systolic dysfunction is associated with impaired outcome,
52 we
also observed an association between systolic dysfunction and
higher in-hospital mortality rates. Our preliminary results
support the need for further investigation in this relatively
unexplored area.
In a subgroup analysis of our study, we also observed an
association between an elevated troponin or presenting in active
atrial ﬁbrillation and higher in-hospital mortality rates. This is
consistent with prior literature. Barasch et al
48 evaluated a small
series of patients with troponin elevation who had no clinical
manifestations of acute coronary syndromes, and concluded
that troponin elevation did not predict hospital mortality.
However, their subset of patients with ischemic and
hemorrhagic strokes accounted for half of the in-hospital
fatalities. James et al
47 evaluated the relation between troponin
T elevation and mortality in AIS patients. Their results
identiﬁed mortality rates of 40% in patients with elevated
troponin T compared with 13% in patients without elevations.
Regarding atrial ﬁbrillation, 1 study suggested that active atrial
ﬁbrillation appears to be a speciﬁc AIS predictor of in-hospital
mortality.
53 However, underlying mechanisms are not well
understood.
Although evidence exists from the SAH literature and
preliminary data in the AIS literature, limited investigation
has evaluated prevalence and inﬂuence of cardiac
complications and hemodynamic derangements in the setting
of AIS. Furthermore, in AIS practice guidelines, no
standardized recommendations promote hemodynamic
monitoring beyond elementary blood pressure control,
checking cardiac biomarkers, and telemetry monitoring. No
recommendations exist for hemodynamic optimization or
augmentation.
10 Despite the paucity of data compared with
those in the neurosurgical literature, our study complements
existing studies, suggesting that AIS patients may acutely
present with decreased contractility. Whether these ﬁndings
occur as a consequence of the AIS, or whether they
predispose individuals to have AIS, we believe this is an area
that merits further investigation and that the data collected
provide a good foundation for future research evaluating the
underlying mechanisms, stroke subtypes at risk, and
treatment alternatives for AIS patients manifesting cardiac
complications.
What does this mean for the EMP managing these
patients? Our results complement existing recommendations to
perform ECGs, measure serum cardiac enzymes, and perform
telemetry monitoring on all AIS patients in the acute
presentation to the ED. Given in our study that only 85% (n¼
171) of patients had ECGs performed in the ED, and that only
80% (n ¼ 161) had cardiac enzymes drawn in the ED, this
potentially is an important area for increased awareness, as
cardiac complications may be associated with a worse outcome
in patients with both large and small strokes. Furthermore, it is
conceivable, given the evolution of the specialty of emergency
medicine, that in the future, bedside ultrasound may be used
noninvasively to estimate preload and evaluate for impaired
contractility. Certainly our specialty literature has demonstrated
that high-quality echocardiograms may be performed by EPs.
54
Additionally, given the dependence of cerebral blood ﬂow on
cardiac function, it is plausible to envision the development of a
stroke goal-directed hemodynamic optimization study aimed at
linking systemic resuscitation in the acute presentation to the
salvation of the penumbra.
In summary, although our study is limited by design,
small sample size, potential bias, and lack of controls, it
suggests that a signiﬁcant proportion of ED AIS patients have
cardiac complications that potentially may be associated with
higher mortality rates. Our data also suggest that patients
with more-severe strokes may be more likely to have
associated cardiac complications. Thus, our results
complement current guidelines,
10 suggesting that cardiac
biomarkers, an ECG, and telemetry monitoring be used in the
ED assessment of all AIS patients. They also support the
need for further investigation in the area of heart–brain
interactions in the setting of AIS.
LIMITATIONS
Our study is limited by its retrospective design and small
sample size. Additionally, we did not have a control group to
identify whether a higher rate of systolic dysfunction occurred
among AIS patients compared with age-matched controls.
Nevertheless, the presence of almost a third of patients having
undifferentiated systolic dysfunction—whether as an
underlying comorbidityor acutely within thesame period asthe
stroke—is a signiﬁcant ﬁnding that merits further
investigation. Limited studies complement our results by
suggesting that undifferentiated systolic dysfunction is
associated with worse functional neurologic outcome.
52
Another limitation is that our method for identifying
patients may have missed AIS patients admitted from the ED
with another diagnosis (ie, altered mental status). However, this
is a common limitation of stroke studies identifying patients in
the ED.
55 Additionally, because of the retrospective design of
the study, a selection bias for the subgroup analyses involved
serum troponin, ECG abnormalities, and red blood cell volume,
as not all patients had these tests performed by treating
physicians in the ED or outpatient setting.
Additionally, a limitation in our study was the use of a
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evaluating hemoconcentration is untested and has potential
bias. Even though we were not aware of any patients receiving
blood transfusions in the ED or taking exogenous
erythropoietin before presentation, which would have biased
these results, we were unable to control for crystalloid volume
administered before laboratory results were determined.
However, we suspect that a large number of patients had blood
drawn before crystalloid administration because in our
institution’s acute stroke protocol, blood is typically drawn
when the ﬁrst intravenous injection is placed before the
administration of any medications or ﬂuids.
Given that echocardiography is a standard of care for all
AIS patients in our institution to potentially identify a source of
the stroke, wewere reassured that only 8 patients were excluded
for not having echocardiograms performed within 72 hours.
However, a limitation of the retrospective nature of this study is
that we were unable to control for concomitant medications or
other variables that may have transiently affected systolic
function when echocardiograms were being performed.
CONCLUSION
A proportion of ED AIS patients may have associated
cardiac complications, either as a direct result of the AIS, or
because of other factors that were not analyzed in this study.
Serum troponin elevation, active atrial ﬁbrillation, ischemic
changes on ECG, and the presence of systolic dysfunction may
be associated with more-severe strokes and with higher in-
hospital mortality rates. These ﬁndings support the adjunctive
role of cardiac-monitoring strategies in the acute presentation
of AIS, and support the need for further research evaluating
heart–brain interactions in the setting of AIS.
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